CVRx

CVRx is a commercial-stage medical device company commercializing Barostim, an implantable neuromodulation device that delivers electrical pulses to carotid baroreceptors to restore baroreflex activation therapy for patients with cardiovascular disease, primarily heart failure. Incorporated in 2000, headquartered in Minneapolis, and listed on Nasdaq in June 2021, the company sells through a direct sales force in the US and Germany. Its August 2026 Q2 report showed $15.7 million in revenue with 87% gross margins but a sharp cut to the full-year 2026 revenue outlook, triggering a roughly 60% single-day repricing and downgrades from Lake Street and Craig-Hallum.